Venture capital firm Amgen Ventures joined a $25 million series A fundraising effort for startup Kernal Biologics.
Kernal Biologics specializes in mRNA technology that they hope will improve cancer patients' survival rate and quality of life. The new financing will be used to further develop these technologies and support an investigational new drug filing with the FDA for one of its cancer therapeutics, according to a July 7 news release.
Hummingbird Ventures led the financing effort, with Amgen Ventures, HBM Genomics and Civilization Ventures joining in.